## Taijyu Satoh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9754214/publications.pdf

Version: 2024-02-01

623734 940533 16 717 14 16 citations h-index g-index papers 16 16 16 1048 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Protective Roles of Endothelial AMP-Activated Protein Kinase Against Hypoxia-Induced Pulmonary Hypertension in Mice. Circulation Research, 2016, 119, 197-209.	4.5	93
2	Basigin Mediates Pulmonary Hypertension by Promoting Inflammation and Vascular Smooth Muscle Cell Proliferation. Circulation Research, 2014, 115, 738-750.	4.5	87
3	Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension. Circulation, 2018, 138, 600-623.	1.6	80
4	BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension. Circulation, 2019, 139, 2238-2255.	1.6	54
5	ADAMTS8 Promotes the Development of Pulmonary Arterial Hypertension and Right Ventricular Failure. Circulation Research, 2019, 125, 884-906.	4.5	52
6	Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 636-646.	2.4	47
7	Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension. Circulation Research, 2017, 120, 1246-1262.	4.5	45
8	Metabolic Syndrome Mediates ROS-miR-193b-NFYA–Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Circulation, 2021, 144, 615-637.	1.6	44
9	Frataxin deficiency promotes endothelial senescence in pulmonary hypertension. Journal of Clinical Investigation, 2021, 131, .	8.2	38
10	Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1293-1301.	2.4	35
11	Small GTP-Binding Protein GDP Dissociation Stimulator Prevents Thoracic Aortic Aneurysm Formation and Rupture by Phenotypic Preservation of Aortic Smooth Muscle Cells. Circulation, 2018, 138, 2413-2433.	1.6	34
12	Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension. Circulation Research, 2019, 125, 309-327.	4.5	34
13	Identification of Emetine as a Therapeutic Agent for Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2367-2385.	2.4	26
14	Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1543-1558.	2.4	20
15	Computational repurposing of therapeutic small molecules from cancer to pulmonary hypertension. Science Advances, 2021, 7, eabh3794.	10.3	16
16	Diagnostic and Prognostic Significance of Serum Levels of SeP (Selenoprotein P) in Patients With Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2553-2562.	2.4	12